Garrett M Frampton

Citada per

	Totes	Des de 2020
Citacions	44579	26554
Índex h	84	71
Índex i10	180	162

6000

3000

1500

4500

200820092010201120122013201420152016201720182019202020212022202320242025141 255 375 635 860 1187 1300 1487 1832 2552 3086 3739 4806 5731 5417 5156 4682 737

Accés públic

Mostra-ho tot

98 articles

0 articles

disponibles

no disponibles

Es basa en els requisits de les agències que proporcionen el finançament

Coautors

Alexa SchrockCorreu electrònic verificat a foundationmedicine.com
Zachary R ChalmersNorthwestern UniversityCorreu electrònic verificat a northwestern.edu
Lee AlbackerDirector, Foundation Medicine Inc.Correu electrònic verificat a foundationmedicine.com
Doron LipsonCSO, Ultima GenomicsCorreu electrònic verificat a ultimagen.com
James X. SunCorreu electrònic verificat a mit.edu
Richard YoungProfessor of Biology, MITCorreu electrònic verificat a wi.mit.edu
Razelle Kurzrock, MDProfessor of Medicine, Medical College of WisconsinCorreu electrònic verificat a mcw.edu
Roman YelenskyCTO, Gritstone OncologyCorreu electrònic verificat a gritstone.com
Sai-Hong Ignatius OuUniversity of California IrvineCorreu electrònic verificat a uci.edu
Samuel Klempner, MDMassachusetts General Hospital, Harvard Medical SchoolCorreu electrònic verificat a partners.org
Matthew GuentherSyros PharmaceuticalsCorreu electrònic verificat a wi.mit.edu
Stuart S. LevineMassachusetts Institute of TechnologyCorreu electrònic verificat a mit.edu
Albert W. Cheng, PhD 郑瑚博士Professor at Institute of Zoology, Chinese Academy of SciencesCorreu electrònic verificat a cheng.bio
Eric M SanfordIcahn School of Medicine at Mount Sinai, Department of PsychiatryCorreu electrònic verificat a mountsinai.org
Alexander MarsonDirector of Gladstone-UCSF Institute of Genomic Immunology, Professor, Department of MedicineCorreu electrònic verificat a ucsf.edu
David OrlandoMOMA TherapeuticsCorreu electrònic verificat a momatx.com
Steve BilodeauCentre de Recherche du CHU de Québec - Université LavalCorreu electrònic verificat a ulaval.ca
Sumeet GuptaWhitehead Institute Of Biomedical ResearchCorreu electrònic verificat a wi.mit.edu
Funda Meric-BernstamChair, Department of Investigational Cancer Therapeutics, The UT MD Anderson Cancer CenterCorreu electrònic verificat a mdanderson.org
Christopher LengnerUniversity of PennsylvaniaCorreu electrònic verificat a vet.upenn.edu

Segueix

Garrett M Frampton

Foundation Medicine Inc.

Correu electrònic verificat a foundationmedicine.com

Genomics Bioinformatics Computational biology Cancer genomics


Títol Ordena per cites Ordena per any Ordena per títol	Citada per Citada per	Any
Histone H3K27ac separates active from poised enhancers and predicts developmental state MP Creyghton, AW Cheng, GG Welstead, T Kooistra, BW Carey, ... Proceedings of the National Academy of Sciences 107 (50), 21931-21936, 2010	4674	2010
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm … JE Rosenberg, J Hoffman-Censits, T Powles, MS Van Der Heijden, ... The Lancet 387 (10031), 1909-1920, 2016	3914	2016
Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden ZR Chalmers, CF Connelly, D Fabrizio, L Gay, SM Ali, R Ennis, A Schrock, ... Genome medicine 9, 1-14, 2017	3221	2017
Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing GM Frampton, A Fichtenholtz, GA Otto, K Wang, SR Downing, J He, ... Nature biotechnology 31 (11), 1023-1031, 2013	2307	2013
Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers AM Goodman, S Kato, L Bazhenova, SP Patel, GM Frampton, V Miller, ... Molecular cancer therapeutics 16 (11), 2598-2608, 2017	2224	2017
Connecting microRNA genes to the core transcriptional regulatory circuitry of embryonic stem cells A Marson, SS Levine, MF Cole, GM Frampton, T Brambrink, S Johnstone, ... cell 134 (3), 521-533, 2008	1788	2008
STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma F Skoulidis, ME Goldberg, DM Greenawalt, MD Hellmann, MM Awad, ... Cancer discovery 8 (7), 822-835, 2018	1401	2018
Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies D Lipson, M Capelletti, R Yelensky, G Otto, A Parker, M Jarosz, JA Curran, ... Nature medicine 18 (3), 382-384, 2012	1095	2012
Densely interconnected transcriptional circuits control cell states in human hematopoiesis N Novershtern, A Subramanian, LN Lawton, RH Mak, WN Haining, ... Cell 144 (2), 296-309, 2011	1094	2011
Foxp3 occupancy and regulation of key target genes during T-cell stimulation A Marson, K Kretschmer, GM Frampton, ES Jacobsen, JK Polansky, ... Nature 445 (7130), 931-935, 2007	975	2007
Co-occurring Genomic Alterations Define Major Subsets of KRAS-Mutant Lung Adenocarcinoma with Distinct Biology, Immune Profiles, and Therapeutic … F Skoulidis, LA Byers, L Diao, VA Papadimitrakopoulou, P Tong, J Izzo, ... Cancer discovery 5 (8), 860-877, 2015	863	2015
Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors GM Frampton, SM Ali, M Rosenzweig, J Chmielecki, X Lu, TM Bauer, ... Cancer discovery 5 (8), 850-859, 2015	815	2015
Emergence of constitutively active estrogen receptor-α mutations in pretreated advanced estrogen receptor–positive breast cancer R Jeselsohn, R Yelensky, G Buchwalter, G Frampton, F Meric-Bernstam, ... Clinical cancer research 20 (7), 1757-1767, 2014	722	2014
Enhancer decommissioning by LSD1 during embryonic stem cell differentiation WA Whyte, S Bilodeau, DA Orlando, HA Hoke, GM Frampton, CT Foster, ... Nature 482 (7384), 221-225, 2012	666	2012
Chromatin structure and gene expression programs of human embryonic and induced pluripotent stem cells MG Guenther, GM Frampton, F Soldner, D Hockemeyer, M Mitalipova, ... Cell stem cell 7 (2), 249-257, 2010	572	2010
Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity H Beltran, R Yelensky, GM Frampton, K Park, SR Downing, ... European urology 63 (5), 920-926, 2013	568	2013
Mechanisms and therapeutic implications of hypermutation in gliomas M Touat, YY Li, AN Boynton, LF Spurr, JB Iorgulescu, CL Bohrson, ... Nature 580 (7804), 517-523, 2020	561	2020
PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers M Yarchoan, LA Albacker, AC Hopkins, M Montesion, K Murugesan, ... JCI insight 4 (6), e126908, 2019	492	2019
Targeted next generation sequencing identifies markers of response to PD-1 blockade DB Johnson, GM Frampton, MJ Rioth, E Yusko, Y Xu, X Guo, RC Ennis, ... Cancer immunology research 4 (11), 959-967, 2016	484	2016
Association of patient characteristics and tumor genomics with clinical outcomes among patients with non–small cell lung cancer using a clinicogenomic database G Singal, PG Miller, V Agarwala, G Li, G Kaushik, D Backenroth, A Gossai, ... Jama 321 (14), 1391-1399, 2019	483	2019

En aquests moments el sistema no pot dur a terme l'operació. Torneu-ho a provar més tard.

Articles 1–20

Cites per any

Cites duplicades

Cites combinades

Addició de coautorsCoautors

Segueix

Citada per

Coautors